Taltz (ixekizumab)

Taltz is a biologic that was approved for the treatment of moderate-to-severe plaque psoriasis in 2016 and for active psoriatic arthritis in 2017.

What is Taltz?

Taltz (also known by its generic name ixekizumab) that was approved for the treatment of moderate-to-severe plaque psoriasis in patients older than 6 years and older in 2016 and for adults with active psoriatic arthritis in 2017.

Taltz is given by injection under the skin. For adults with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment) and at weeks 2, 4, 6, 8, 10, and 12, and then every 4 weeks afterwards. For pediatric patients with plaque psoriasis, the initial dose is given at week 0 (the first week of treatment) and then every 4 weeks afterwards. For adults with psoriatic arthritis, the initial dose is given at week 0 (the first week of treatment) and then every 4 weeks afterwards.

To learn more, please visit the Taltz website.

FDA Approves Skyrizi for Plaque Psoriasis

Learn how Skyrizi could be a treatment option for you and your psoriasis.

Find out more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.